全文获取类型
收费全文 | 28608篇 |
免费 | 1708篇 |
国内免费 | 241篇 |
专业分类
耳鼻咽喉 | 237篇 |
儿科学 | 564篇 |
妇产科学 | 596篇 |
基础医学 | 2943篇 |
口腔科学 | 769篇 |
临床医学 | 2004篇 |
内科学 | 8042篇 |
皮肤病学 | 355篇 |
神经病学 | 2628篇 |
特种医学 | 1080篇 |
外科学 | 5484篇 |
综合类 | 56篇 |
一般理论 | 6篇 |
预防医学 | 1048篇 |
眼科学 | 527篇 |
药学 | 1671篇 |
中国医学 | 55篇 |
肿瘤学 | 2492篇 |
出版年
2023年 | 275篇 |
2022年 | 242篇 |
2021年 | 866篇 |
2020年 | 599篇 |
2019年 | 856篇 |
2018年 | 1038篇 |
2017年 | 757篇 |
2016年 | 886篇 |
2015年 | 932篇 |
2014年 | 1242篇 |
2013年 | 1547篇 |
2012年 | 2365篇 |
2011年 | 2237篇 |
2010年 | 1297篇 |
2009年 | 1245篇 |
2008年 | 1931篇 |
2007年 | 1864篇 |
2006年 | 1762篇 |
2005年 | 1753篇 |
2004年 | 1660篇 |
2003年 | 1402篇 |
2002年 | 1278篇 |
2001年 | 167篇 |
2000年 | 162篇 |
1999年 | 189篇 |
1998年 | 183篇 |
1997年 | 144篇 |
1996年 | 139篇 |
1995年 | 163篇 |
1994年 | 139篇 |
1993年 | 126篇 |
1992年 | 141篇 |
1991年 | 93篇 |
1990年 | 93篇 |
1989年 | 66篇 |
1988年 | 61篇 |
1987年 | 55篇 |
1986年 | 63篇 |
1985年 | 57篇 |
1984年 | 49篇 |
1983年 | 47篇 |
1982年 | 58篇 |
1981年 | 35篇 |
1980年 | 32篇 |
1979年 | 30篇 |
1978年 | 23篇 |
1976年 | 16篇 |
1975年 | 18篇 |
1974年 | 23篇 |
1973年 | 14篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Ruscitti Piero Di Cola Ilenia Berardicurti Onorina Conforti Alessandro Iacono Daniela Pantano Ilenia Rozza Gelsomina Rossi Silvia De Stefano Ludovico Balduzzi Silvia Vitale Antonio Caso Francesco Costa Luisa Prete Marcella Navarini Luca Atzeni Fabiola Guggino Giuliana Perosa Federico Cantarini Luca Frediani Bruno Montecucco Carlomaurizio Ciccia Francesco Giacomelli Roberto Cipriani Paola 《Clinical rheumatology》2022,41(11):3597-3597
Clinical Rheumatology - 相似文献
2.
Cifuentes-Faura Javier Di Francesco Renaud 《The European journal of health economics》2022,23(4):559-563
The European Journal of Health Economics - 相似文献
3.
Naveen Pemmaraju MD Jacqueline S. Garcia MD Andrew Perkins MBBS PhD Jason G. Harb PhD Andrew J. Souers PhD Michael E. Werner PhD Christopher M. Brown PhD Francesco Passamonti MD 《Cancer》2023,129(22):3535-3545
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment. 相似文献
4.
Foc Emanuele Fornari Chiara Arsuffi Stefania Vetrano Maria Chiara Calza Stefano Renzetti Stefano Copeta Silvia Berruti Alfredo Castelli Francesco Compostella Silvia Quiros-Roldan Eugenia 《AIDS and behavior》2022,26(9):2920-2930
AIDS and Behavior - People living with chronic disease (PLWCD) are the frailest category, both for the risk of severe COVID-19 illness and for the impact on the care continuum. Aim of this study... 相似文献
5.
6.
7.
Johnson Stephen Kano Hideyuki Faramand Andrew Pease Matthew Nakamura Aya Hassib Mohab Spencer David Sisterson Nathaniel Faraji Amir H. Arai Yoshio Monaco Edward Niranjan Ajay Flickinger John C. Lunsford L. Dade 《Journal of neuro-oncology》2019,145(2):247-255
Journal of Neuro-Oncology - Stereotactic radiosurgery (SRS) has become a primary option for management for both newly diagnosed vestibular schwannomas (VS), as well as VS that enlarge after initial... 相似文献
8.
Marco Bandini Sebastiano Nazzani Michele Marchioni Felix Preisser Zhe Tian Marco Moschini Firas Abdollah Nazareno Suardi Markus Graefen Francesco Montorsi Shahrokh F. Shariat Fred Saad Alberto Briganti Pierre I. Karakiewicz 《Clinical genitourinary cancer》2019,17(1):72-78.e4
Background
The rate of noninterventional treatment (NIT) in prostate cancer (PCa) active surveillance (AS) candidates is on the rise. However, contemporary data are unavailable. We described community-based NIT rates within 16 Surveillance Epidemiology and End Results (SEER) registries between 2010 and 2014.Patients and Methods
We identified 23,360 PCa patients who fulfilled the University of California San Francisco AS criteria (prostate-specific antigen [PSA] < 10 ng/mL, clinical T stage ≤ T2a, Gleason score ≤ 6, and positive cores < 33%). Annual NIT rates as well as patient distribution according to PSA, age, number of positive cores, and clinical T stage were studied. Multivariable logistic regression analysis tested NIT predictors.Results
Between 2010 and 2014, the NIT rate increased from 30.2% to 57.5% (P = .004). Within 16 SEER registries, NIT rates ranged from 25.9% to 62%. NIT rate increased uniformly within all examined registries. Of patient and tumor characteristics (PSA > 4 ng/mL, cT2a and > 1 positive core) only the proportion of NIT patients aged < 65 years increased over time from 47.3% to 53.2% (P = .03). By multivariable logistic regression analysis predicting NIT rate, older age (odd ratio [OR] = 1.05), more contemporary year of diagnosis (OR = 1.41), and being unmarried (OR = 1.45) and uninsured (OR = 2.41) were independent predictors.Conclusion
The NIT rate has markedly increased across all examined SEER registries. Nonetheless, important differences distinguish those who received high-end NIT from low-end NIT. PCa characteristics of NIT patients remained unchanged over time. However, in addition to geographical differences in NIT rates, patient characteristics such as age, marital status, and insurance status represent potential NIT access barriers. 相似文献9.
Vincenzo Di Nunno Veronica Mollica Matteo Santoni Lidia Gatto Riccardo Schiavina Michelangelo Fiorentino Eugenio Brunocilla Andrea Ardizzoni Francesco Massari 《Clinical genitourinary cancer》2019,17(5):e871-e877
In the past few years several hormonal agents have been tested in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) leading to an impressive improvement in terms of metastases-free survival (MFS). We performed a meta-analysis aimed to: (1) estimate the pooled effect of new hormonal compounds in terms of MFS, overall survival (OS) in overall and specific subpopulations; and (2) estimate the effect of high-grade toxicities of these drugs. We identified 881 studies published between January 1, 2010 and February 16, 2018 on PubMed/Medline, Cochrane Library, and Scopus. Three randomized placebo controlled clinical trials were selected (PROSPER, SPARTAN, and ARAMIS). Because of the absence of individual data, all of the analyses performed were made on aggregated data provided in selected studies. We used the inverse variance technique for the meta-analysis of the hazard ratios collected for MFS and OS analysis. Fixed and randomized models were used. Relative risk and 95% confidence intervals and risk difference were estimated considering the number of Grade 3 adverse events in treatment and control arms. Administration of new hormonal compounds in nmCRPC patients led to a significant benefit in MFS in the overall population and in all subgroups analyzed. These agents might also improve OS but longer follow-up is needed to confirm this hypothesis. Indeed results of OS analysis should be carefully evaluated because none of the studies selected provided mature OS data. Administration of these agents resulted in a significant increased risk of treatment-related death, high cardiovascular toxicity, hypertension, fractures, and falls. Administration of new hormonal compounds prolongs the time of metastases occurrence and might prolong also survival in patients with nmCRPC. Treatment-related toxicity is an important issue because these agents increase the risk of death, cardiovascular toxicity, hypertension, fractures, and risk of falls. 相似文献
10.
Michael Belingheri Rita Facchetti Francesco Scordo Francesco Butturini Massimo Turato Giovanni De Vito Giancarlo Cesana Michele Augusto Riva 《La Medicina del lavoro》2019,110(2):155
Background:Risk behaviors are frequent among young adults and they are particularly relevant when considering healthcare students.Objectives:The study is aimed to examine the prevalence of smoking, binge drinking, physical inactivity, and excessive bodyweight in a population of healthcare students attending an Italian university.Methods:Healthcare students filled an anonymous multiple-choice questionnaire on the occasion of the occupational health visit that preceded their hospital internship. The questionnaire covered socio-demographic characteristics (including student’s working status and cohabitation) and risk behaviors. We evaluated the prevalence of risk behaviors and their association with socio-demographic characteristics.Results:The sample consisted of 494 students (65% women): 23.2% were smokers, 7.9% had excessive bodyweight, 35% did not practice any physical activity and 50% reported binge drinking at least once in the last 12 months. We found associations of male sex (30.5%) and being nursing students (29.9%) with smoking habit. The frequency of binge drinking was higher in men (38.4%), working students (53.9%), and among those who lived without family (50%). Physical inactivity was associated with female sex (44.2%) and living without family (57.1%). Finally, the co-presence of 2 risk behaviors or more was higher in men (36.8%), in nursing students (39.6%) and in working students (44.7%).Conclusions:Our findings regarding the prevalence of risk behaviors and their potential association with socio-demographic factors may be a clue to the definition of targeted strategies aimed at reducing of risk behaviors among healthcare students.Key words: risk behaviors, healthcare students, smoking, binge drinking, physical inactivity 相似文献